News

The R3 antibody, generated by Affitech and tested by Peregrine Pharmaceuticals, has been designed by the two companies for selective blocking of VEGF (vascular endothelial growth factor) binding

AtheroGenics will reacquire all worldwide rights for AGI-1067 and will continue to develop the compound, the company said. AstraZeneca is responsible for providing transition support to AtheroGenics. “Based

Pfizer is seeking approval for maraviroc in patients already taking other drugs. If approved, it will be the first drug available in the class called CCR5 antagonists. CCR5

Researchers from PTC and at the University of Pennsylvania School of Medicine have for the first time demonstrated restoration of muscle function in a mouse model of Duchenne’s

Simcor contains Niaspan – used to raise HDL “good” cholesterol levels, and simvastatin – used to reduce LDL “bad” cholesterol levels. This combination is being submitted for FDA

The acquisition price represents a premium of approximately 53% to US-based MedImmune’s closing share price of $37.84 on 11th April, 2007, the day before the company indicated that

This new approach will replace a system of whereby AstraZeneca would use a number of wholesalers to supply drugs. The move is similar to an agreement made by

SuperGen will receive $600,000 shortly after signing with the balance due at the time of product transfer later this quarter. SuperGen will also sell for additional consideration certain

The results of the trial showed that once daily administration of Lovenox 40mg was more effective than unfractionated heparin twice a day for the prevention of blood clots